KB-1850

Etokimab

61524

Background of Etokimab

Etokimab (ANB020), a humanized IgG1 antibody directed against IL-33, was evaluated in a phase 2a study in 12 adult patients with moderate to severe AD. After a single intravenous dose of 300 mg, rapid and marked clinical benefit was observed, with 83% of patients achieving EASI-50 by day 29 and 33% achieving EASI-75, with sustained improvement through day 57. Treatment significantly reduced peripheral blood eosinophil counts (by ~40% on average) and reduced neutrophil infiltration in the skin after allergen (house dust mite) provocation. In ex vivo studies, etokimab inhibited IL-33-induced neutrophil migration and secondarily reduced their sensitivity to IL-8 by inhibiting CXCR1 receptor expression, confirming its immunomodulatory effect on the IL-33-CXCR1 axis.

Specifications

Catalog Number	KB-1850
Antibody Name	Etokimab
Isotype	Human IgG1,kappa
FC Muations	Wild Type
Target	IL33
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Chen YL, Gutowska-Owsiak D, Hardman CS, Westmoreland M, MacKenzie T, Cifuentes L, Waithe D, Lloyd-Lavery A, Marquette A, Londei M, Ogg G. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Sci Transl Med. 2019 Oct 23;11(515):eaax2945.